We serve Chemical Name:4-hydroxy-N-pyrazin-2-ylbenzenesulfonamide CAS:872825-57-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-hydroxy-N-pyrazin-2-ylbenzenesulfonamide
CAS.NO:872825-57-5
Synonyms:N-(Pyrazinlyl)-1-phenol-4-sulfonamide
Molecular Formula:C10H9N3O3S
Molecular Weight:251.26200
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:482ºC at 760 mmHg
Density:1.537g/cm3
Index of Refraction:1.67
PSA:100.56000
Exact Mass:251.03600
LogP:2.13680
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like N-(Pyrazinlyl)-1-phenol-4-sulfonamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-(Pyrazinlyl)-1-phenol-4-sulfonamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(Pyrazinlyl)-1-phenol-4-sulfonamide Use and application,N-(Pyrazinlyl)-1-phenol-4-sulfonamide technical grade,usp/ep/jp grade.
Related News: Delta moved the date up after the US State Department warned that people should not travel to China due to concerns about the spread of coronavirus, which was first discovered in Wuhan, Hubei province, in December. 4-hydroxy-N-pyrazin-2-ylbenzenesulfonamide manufacturer Our pharma and biotech offering includes registration and commercialization of products through in-licensing and flexible partnerships. 4-hydroxy-N-pyrazin-2-ylbenzenesulfonamide supplier It is frequently associated with the presence of blasts or leukemic cells in the marrow. 4-hydroxy-N-pyrazin-2-ylbenzenesulfonamide vendor The Company��s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. 4-hydroxy-N-pyrazin-2-ylbenzenesulfonamide factory The Biogen Inc (BIIB.O) drug, Aduhelm, was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer’s, rather than proof that it slows progression of the lethal mind-wasting disease.
